Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according ...
7 hours ago
0
1